Loading stock data…
$7.39+0.15 (+2.07%)
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
LeonaBio, Inc. in the Healthcare sector is trading at $7.39 with a market capitalization of $85M. Wall Street consensus targets $18.00 (2 analysts), implying a +143.6% move over the next 12 months. The stock is currently 48% below its 52-week high of $14.21, remaining 6.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.14M↓ | -$10.48M↓ | -$6.87M↑ | -$7.29M↑ | -$9.54M |
| Net Income | -$32.95M↑ | -$82.89M↓ | -$6.61M↑ | -$6.97M↑ | -$9.14M |
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead prod...